USTR's new Section 301 investigation targeting Germany's drug pricing, combined with Section 232 pharmaceutical tariffs, signals a coordinated multistatute trade strategy.
| less than a minute read
Germany in the Crosshairs: USTR’s New Section 301 Drug Pricing Investigation and What It Means Alongside the Section 232 Pharmaceutical Tariff Regime
Get in touch
Get in touch
Get in touch
Get in touch
Latest Insights
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-09-28-17-19-51-732-6abaa1b7a556c8efb06ae860.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-09-28-13-12-53-492-6aba67d5a556c8efb06a4843.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-09-28-13-10-53-958-6aba675d9a7b7dedf3b58a8f.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-09-28-13-11-25-980-6aba677dfe1eb48719945e90.jpg)